Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1987 Sep;31(9):1383–1387. doi: 10.1128/aac.31.9.1383

Univariate and multivariate analyses of risk factors predisposing to auditory toxicity in patients receiving aminoglycosides.

J M Gatell 1, F Ferran 1, V Araujo 1, M Bonet 1, E Soriano 1, J Traserra 1, J G SanMiguel 1
PMCID: PMC174947  PMID: 3674849

Abstract

Risk factors predisposing to auditory toxicity of aminoglycosides were analyzed from records of 187 patients enrolled in three prospective randomized trials comparing the toxicity of netilmicin, tobramycin, and amikacin. Patients were eligible if they received three or more days of therapy and at least two serial audiograms were available. The overall auditory toxicity rate was 9.6% (18 of 187). Auditory toxicity was detected in 4.4, 10.8, and 23.5% of patients given netilmicin, tobramycin, and amikacin, respectively (P = 0.05). In the univariate analysis, patients who developed auditory toxicity were significantly older (P = 0.01) and had a significantly higher (P = 0.04) percentage of trough levels of netilmicin or tobramycin above 2 mg/liter or amikacin above 5 mg/liter. In the final logistic regression model, only age was retained as independently influencing the development of auditory toxicity (P less than 0.00001). Conversely, factors that did not add significantly to the prediction of auditory toxicity were aminoglycoside serum levels, total aminoglycoside dose, duration of therapy, sex, peak temperature, presence of bacteremia, shock, liver cirrhosis, dehydration, previous otic pathology or renal failure, and development of renal toxicity. At least in certain populations, age is the most important predisposing factor for the development of auditory toxicity in patients receiving aminoglycosides.

Full text

PDF
1386

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barends D. M., Zwaan C. L., Hulshoff A. Micro-determination of tobramycin in serum by high-performance liquid chromatography with ultraviolet detection. J Chromatogr. 1981 Oct 9;225(2):417–426. doi: 10.1016/s0378-4347(00)80289-3. [DOI] [PubMed] [Google Scholar]
  2. Barza M., Lauermann M. W., Tally F. P., Gorbach S. L. Prospective, randomized trial of netilmicin and amikacin, with emphasis on eighth-nerve toxicity. Antimicrob Agents Chemother. 1980 Apr;17(4):707–714. doi: 10.1128/aac.17.4.707. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Brummett R. E., Fox K. E., Brown R. T., Himes D. L. Comparative ototoxic liability of netilmicin and gentamicin. Arch Otolaryngol. 1978 Oct;104(10):579–584. doi: 10.1001/archotol.1978.00790100033007. [DOI] [PubMed] [Google Scholar]
  4. Brummett R. E., Jackson R. T. Age related changes influencing the effects of drugs and other xenobiotics on sensorineural hearing. Pharmacol Ther. 1984;26(2):209–219. doi: 10.1016/0163-7258(84)90017-2. [DOI] [PubMed] [Google Scholar]
  5. Dulon D., Aran J. M., Zajic G., Schacht J. Comparative uptake of gentamicin, netilmicin, and amikacin in the guinea pig cochlea and vestibule. Antimicrob Agents Chemother. 1986 Jul;30(1):96–100. doi: 10.1128/aac.30.1.96. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Fee W. E., Jr Aminoglycoside ototoxicity in the human. Laryngoscope. 1980 Oct;90(10 Pt 2 Suppl 24):1–19. doi: 10.1288/00005537-198010001-00001. [DOI] [PubMed] [Google Scholar]
  7. Gatell J. M., San Miguel J. G., Zamora L., Araujo V., Bonet M., Bohé M., Jimenez de Anta M. T., Farré M., Elena M., Ballesta A. Comparison of the nephrotoxicity and auditory toxicity of tobramycin and amikacin. Antimicrob Agents Chemother. 1983 Jun;23(6):897–901. doi: 10.1128/aac.23.6.897. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Gatell J. M., SanMiguel J. G., Araujo V., Zamora L., Maña J., Ferrer M., Bonet M., Bohe M., Jimenez de Anta M. T. Prospective randomized double-blind comparison of nephrotoxicity and auditory toxicity of tobramycin and netilmicin. Antimicrob Agents Chemother. 1984 Nov;26(5):766–769. doi: 10.1128/aac.26.5.766. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Gatell J. M., SanMiguel J. G., Zamora L., Araujo V., Castells C., Moreno A., Jimenez de Anta M. T., Marin J. L., Elena M., Ballesta A. Tobramycin and amikacin nephrotoxicity. Value of serum creatinine versus urinary concentration of beta-2-microglobulin. Nephron. 1985;41(4):337–343. doi: 10.1159/000183611. [DOI] [PubMed] [Google Scholar]
  10. Henry K. R., Guess M. B., Chole R. A. Hyperthermia increases aminoglycoside ototoxicity. Acta Otolaryngol. 1983 Mar-Apr;95(3-4):323–327. doi: 10.3109/00016488309130949. [DOI] [PubMed] [Google Scholar]
  11. Igarashi M., Levy J. K., Jerger J. Comparative toxicity of netilmicin and gentamicin in squirrel monkeys (Saimiri sciureus). J Infect Dis. 1978 Apr;137(4):476–480. doi: 10.1093/infdis/137.4.476. [DOI] [PubMed] [Google Scholar]
  12. Jahre J. A., Fu K. P., Neu H. C. Clinical evaluation of netilmicin therapy in serious infections. Am J Med. 1979 Jan;66(1):67–73. doi: 10.1016/0002-9343(79)90484-4. [DOI] [PubMed] [Google Scholar]
  13. Jauhiainen T., Kohonen A., Jauhiainen M. Combined effect of noise and neomycin on the cochlea. Acta Otolaryngol. 1972 May;73(5):387–390. doi: 10.3109/00016487209138956. [DOI] [PubMed] [Google Scholar]
  14. Lerner A. M., Reyes M. P., Cone L. A., Blair D. C., Jansen W., Wright G. E., Lorber R. R. Randomised, controlled trial of the comparative efficacy, auditory toxicity, and nephrotoxicity of tobramycin and netilmicin. Lancet. 1983 May 21;1(8334):1123–1126. doi: 10.1016/s0140-6736(83)92864-7. [DOI] [PubMed] [Google Scholar]
  15. Lerner S. A., Seligsohn R., Matz G. J. Comparative clinical studies of ototoxicity and nephrotoxicity of amikacin and gentamicin. Am J Med. 1977 Jun;62(6):919–923. doi: 10.1016/0002-9343(77)90661-1. [DOI] [PubMed] [Google Scholar]
  16. Luft F. C., Bloch R., Sloan R. S., Yum M. N., Costello R., Maxwell D. R. Comparative nephrotoxicity of aminoglycoside antibiotics in rats. J Infect Dis. 1978 Oct;138(4):541–545. doi: 10.1093/infdis/138.4.541. [DOI] [PubMed] [Google Scholar]
  17. Maigaard S., Frimodt-Möller N., Madsen P. O. Comparison of netilmicin and amikacin in treatment of complicated urinary tract infections. Antimicrob Agents Chemother. 1978 Oct;14(4):544–548. doi: 10.1128/aac.14.4.544. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Moellering R. C., Jr Have the new beta-lactams rendered the aminoglycosides obsolete for the treatment of serious nosocomial infections? Am J Med. 1986 Jun 30;80(6B):44–47. doi: 10.1016/0002-9343(86)90478-x. [DOI] [PubMed] [Google Scholar]
  19. Moore R. D., Smith C. R., Lietman P. S. Risk factors for the development of auditory toxicity in patients receiving aminoglycosides. J Infect Dis. 1984 Jan;149(1):23–30. doi: 10.1093/infdis/149.1.23. [DOI] [PubMed] [Google Scholar]
  20. Neu H. C., Bendush C. L. Ototoxicity of tobramycin: a clinical overview. J Infect Dis. 1976 Aug;134 (Suppl):S206–S218. doi: 10.1093/infdis/134.supplement_1.s206. [DOI] [PubMed] [Google Scholar]
  21. Parker R. A., Gilbert D. N., Houghton D. C., Porter G. A., Bennett W. M. Comparative nephrotoxicities of high-dose netilmicin and tobramycin in rats. Antimicrob Agents Chemother. 1980 Aug;18(2):346–348. doi: 10.1128/aac.18.2.346. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Prazma J., Ferguson S. D., Kidwell S. A., Garrison H. G., Drake A., Fischer J. Alteration of aminoglycoside antibiotic ototoxicity by hyper- and hypohydration. Am J Otolaryngol. 1981 Nov;2(4):299–306. doi: 10.1016/s0196-0709(81)80039-7. [DOI] [PubMed] [Google Scholar]
  23. Prazma J., Garrison H. G., Williford S. K., Ferguson S. D., Fischer J., Drake A., Klingler L. E. Alteration of aminoglycoside antibiotic ototoxicity: effect of semistarvation. Ann Otol Rhinol Laryngol. 1983 Mar-Apr;92(2 Pt 1):178–182. doi: 10.1177/000348948309200216. [DOI] [PubMed] [Google Scholar]
  24. Sarubbi F. A., Jr, Hull J. H. Amikacin serum concentrations: prediction of levels and dosage guidelines. Ann Intern Med. 1978 Nov;89(5 Pt 1):612–618. doi: 10.7326/0003-4819-89-5-612. [DOI] [PubMed] [Google Scholar]
  25. Sawyers C. L., Moore R. D., Lerner S. A., Smith C. R. A model for predicting nephrotoxicity in patients treated with aminoglycosides. J Infect Dis. 1986 Jun;153(6):1062–1068. doi: 10.1093/infdis/153.6.1062. [DOI] [PubMed] [Google Scholar]
  26. Siegenthaler W. E., Bonetti A., Luthy R. Aminoglycoside antibiotics in infectious diseases. An overview. Am J Med. 1986 Jun 30;80(6B):2–14. doi: 10.1016/0002-9343(86)90473-0. [DOI] [PubMed] [Google Scholar]
  27. Smith C. R., Baughman K. L., Edwards C. Q., Rogers J. F., Lietman P. S. Controlled comparison of amikacin and gentamicin. N Engl J Med. 1977 Feb 17;296(7):349–353. doi: 10.1056/NEJM197702172960701. [DOI] [PubMed] [Google Scholar]
  28. Smith C. R., Lietman P. S. Effect of furosemide on aminoglycoside-induced nephrotoxicity and auditory toxicity in humans. Antimicrob Agents Chemother. 1983 Jan;23(1):133–137. doi: 10.1128/aac.23.1.133. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Smith C. R., Lipsky J. J., Laskin O. L., Hellmann D. B., Mellits E. D., Longstreth J., Lietman P. S. Double-blind comparison of the nephrotoxicity and auditory toxicity of gentamicin and tobramycin. N Engl J Med. 1980 May 15;302(20):1106–1109. doi: 10.1056/NEJM198005153022002. [DOI] [PubMed] [Google Scholar]
  30. Smith C. R., Lipsky J. J., Lietman P. S. Relationship between aminoglycoside-induced nephrotoxicity and auditory toxicity. Antimicrob Agents Chemother. 1979 Jun;15(6):780–782. doi: 10.1128/aac.15.6.780. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Snydman D. R., Tally F. P., Landesman S. H., Barza M., Gorbach S. L. Netilmicin in gram-negative bacterial infections. Antimicrob Agents Chemother. 1979 Jan;15(1):50–54. doi: 10.1128/aac.15.1.50. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Tablan O. C., Reyes M. P., Rintelmann W. F., Lerner A. M. Renal and auditory toxicity of high-dose, prolonged therapy with gentamicin and tobramycin in pseudomonas endocarditis. J Infect Dis. 1984 Feb;149(2):257–263. doi: 10.1093/infdis/149.2.257. [DOI] [PubMed] [Google Scholar]
  33. Trestman I., Parsons J., Santoro J., Goodhart G., Kaye D. Pharmacology and efficacy of netilmicin. Antimicrob Agents Chemother. 1978 May;13(5):832–836. doi: 10.1128/aac.13.5.832. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Wilson P., Ramsden R. T. Immediate effects of tobramycin on human cochlea and correlation with serum tobramycin levels. Br Med J. 1977 Jan 29;1(6056):259–261. doi: 10.1136/bmj.1.6056.259. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Young L. S. Empirical antimicrobial therapy in the neutropenic host. N Engl J Med. 1986 Aug 28;315(9):580–581. doi: 10.1056/NEJM198608283150910. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES